Skip to content

Zydus Lifesciences Limited Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Mon, Feb 8, 2027, before the market opens · estimates and history

Zydus Lifesciences Limited · E.ZYDUSLIFE.NSE · India
Use symbol E.ZYDUSLIFE.NSE in our API & Excel add-in to retrieve this data ↓
1,240.50
(0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 28.19%

Zydus Lifesciences Limited Forecast

Zydus Lifesciences Limited short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 28.2% a year, a typical one-standard-deviation range is 1,191–1,290 over a week, 1,140–1,341 over a month and 890.76–1,590 over a year. (Signals as of 5 Nov 2026.)

Zydus Lifesciences Limited Price Chart

MacroFinance.ai

Zydus Lifesciences Limited Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Zydus Lifesciences Limited
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Zydus Lifesciences Limited
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Zydus Lifesciences Limited
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Zydus Lifesciences Limited
P/E
29.62x
Stretched vs own history
QoQ +18.7%
YoY +56.6%
now 29.618417.24 low29.74 high
ⓘP/E As of 22 Nov 2026.See Zydus Lifesciences Limited returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Zydus Lifesciences Limited
P/S
4.08x
Mid-range vs own history
QoQ +3.5%
YoY +7.3%
now 4.07543.2 low4.23 high
ⓘP/S As of 22 Nov 2026.See Zydus Lifesciences Limited returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Zydus Lifesciences Limited
P/B
4.45x
Mid-range vs own history
QoQ +16.9%
YoY +21.0%
now 4.45053.11 low4.47 high
ⓘP/B As of 22 Nov 2026.See Zydus Lifesciences Limited returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Zydus Lifesciences Limited
EV/EBITDA
17.07x
Stretched vs own history
QoQ +21.3%
YoY +33.4%
now 17.072511.17 low17.14 high
ⓘEV/EBITDA As of 22 Nov 2026.See Zydus Lifesciences Limited returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Zydus Lifesciences Limited
EV/Sales
4.36x
Mid-range vs own history
QoQ +2.0%
YoY +11.7%
now 4.36343.4 low4.38 high
ⓘEV/Sales As of 22 Nov 2026.See Zydus Lifesciences Limited returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Zydus Lifesciences Limited
Earnings Yield
3.4%
Weak vs own history
QoQ −15.8%
YoY −36.1%
now 3.37633.36 low5.8 high
ⓘEarnings Yield As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Zydus Lifesciences Limited
Market Cap
$1.24T
Highest in 5 years
QoQ +10.0%
YoY +33.0%
now 1238019869,123 low1,243,009 high
ⓘMarket Cap As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Zydus Lifesciences Limited
Net Debt
$87.5B
High vs own history
QoQ +65.0%
YoY +240.8%
now 8750525,676 low87,505 high
ⓘNet Debt As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Zydus Lifesciences Limited
Net Debt / EBITDA
1.13x
High vs own history
QoQ +75.4%
YoY +228.0%
now 1.1270.34 low1.13 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Zydus Lifesciences Limited
Current Ratio
1.02x
Weak vs own history
QoQ −19.3%
YoY −47.2%
now 1.02271.02 low1.94 high
ⓘCurrent Ratio As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Zydus Lifesciences Limited
Quick Ratio
0.64x
Weak vs own history
QoQ −29.5%
YoY −55.4%
now 0.64090.64 low1.44 high
ⓘQuick Ratio As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Zydus Lifesciences Limited
Interest Coverage
9.63x
Weak vs own history
QoQ −22.9%
YoY −56.1%
now 9.62739.63 low21.95 high
ⓘInterest Coverage As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Zydus Lifesciences Limited
Debt / Equity
0.50x
High vs own history
QoQ +8.9%
YoY +31.8%
now 0.50210.38 low0.5 high
ⓘDebt / Equity As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Zydus Lifesciences Limited
Piotroski F-Score
2
Weak vs own history
QoQ 0.0%
YoY 0.0%
ⓘPiotroski F-Score As of 22 Nov 2026.See Zydus Lifesciences Limited returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
  14 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  15 members-only factors: Beneish M-Score, Days Sales in Receivables Index, Gross Margin Index, Asset Quality Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Zydus Lifesciences Limited, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Zydus Lifesciences Limited fundamentals: income statement, balance sheet & cash flow

Zydus Lifesciences Limited reported revenue of 271.48bn INR and net income of 50.40bn INR in FY2026, the year ended 31 March 2026 — revenue up 16.8% and net income up 11.4% on the prior year. Free cash flow was -12.03bn INR. These figures are as reported in the filings, not restated: 23 fiscal years and 61 quarters of history, back to March 2004.

Revenue (FY2026)
271.48bn INR
+16.8%
Net income
50.40bn INR
+11.4%
Gross margin
51.68%
Free cash flow
-12.03bn INR
-123.7%
Net debt
110.79bn INR
Zydus Lifesciences Limited income statement, annual, as reported · INR billions unless stated
INR billionsFY2026FY2025FY2024FY2023FY2022
Period end31 Mar 202631 Mar 202531 Mar 202431 Mar 202331 Mar 2022
Revenue271.48232.42195.47172.37151.10
Cost of revenue131.1965.3863.9464.7156.86
Gross profit140.30167.03131.54107.6794.24
Research & development22.7319.4513.1312.4110.46
Operating income57.8796.0475.9657.6151.29
EBITDA85.6568.7653.0335.7632.10
Interest expense4.390.990.491.301.20
Pre-tax income67.1860.8549.2726.8428.84
Income tax15.9514.129.785.885.12
Net income50.4045.2638.6019.6044.87

Download Zydus Lifesciences Limited fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ZYDUSLIFE.NSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 23 fiscal years and 61 quarters, the filing vintages behind each number and API access.
Create free account

Figures in INR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on Zydus Lifesciences Limited

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Zydus Lifesciences Limited Trading Strategies

28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to Zydus Lifesciences Limited; 2 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 28 strategies holding EEM →

Statistical Distribution of Returns

Plus

How Zydus Lifesciences Limited’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Zydus Lifesciences Limited behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Zydus Lifesciences Limited (India)

Zydus Lifesciences Limited is a listed security in India. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Zydus Lifesciences Limited?
Zydus Lifesciences Limited is a listed security in India. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Zydus Lifesciences Limited price?
The latest close is 1,241 (5 Nov 2026), -0.00% on the day. The price at the top of the page refreshes during the trading day.
Is Zydus Lifesciences Limited in an uptrend?
As of 5 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Zydus Lifesciences Limited?
20-day realised volatility is 28.2% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 8.1% over a month and 4.0% over a week.
What factors affect Zydus Lifesciences Limited?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Zydus Lifesciences Limited, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Zydus Lifesciences Limited?
28 backtested tactical asset allocation strategies trade Zydus Lifesciences Limited through EEM; 2 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Zydus Lifesciences Limited returns analysed?
The Statistical Distribution of Returns section shows the distribution of Zydus Lifesciences Limited daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Zydus Lifesciences Limited historical data?
In the Free historical data section of this page: the last 10 years of Zydus Lifesciences Limited daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Zydus Lifesciences Limited historical data (last 10 years)

Browse or instantly download the last 10 years of Zydus Lifesciences Limited daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ZYDUSLIFE.NSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-201200
2026-11-191202.9
2026-11-181202
2026-11-171204.2
2026-11-161192
2026-11-131189.9
2026-11-121206
2026-11-111199.5
2026-11-091215.9
2026-11-081199.5
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.